Autologous stem cell transfected with SCID-X gene (AP-HP/Inserm/Institut Pasteur/Avax)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous stem cell transfected with SCID-X gene (AP-HP/Inserm/Institut Pasteur/Avax)
Drug Alias Nameautologous stem cell therapy genetically enginereed to express SCID-X gene (SCID-X)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionIL-2RG gene transference
TargetsInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsImmunologic Deficiency Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesInstitute of Immunology and Infection, Chinese Academy of Sciences ShanghaiAssistance Publique Hopitaux De ParisInserm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInsermAssistance Publique Hopitaux De ParisInstitute of Immunology and Infection, Chinese Academy of Sciences Shanghai
Active IndicationsN/A
Inactive IndicationsImmunologic Deficiency Syndromes

Other Information

ATC CodeN/A
Related LinksN/A